Cellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 228,602 shares, a decline of 60.4% from the June 15th total of 577,279 shares. Based on an average daily volume of 155,602 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.2% of the company’s stock are sold short.
In other Cellular Biomedicine Group news, CEO Tony Liu purchased 10,000 shares of Cellular Biomedicine Group stock in a transaction dated Tuesday, June 6th. The stock was acquired at an average price of $6.83 per share, for a total transaction of $68,300.00. Following the acquisition, the chief executive officer now owns 119,825 shares in the company, valued at approximately $818,404.75. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.20% of the company’s stock.
Separately, Maxim Group restated a “buy” rating and set a $18.00 price target on shares of Cellular Biomedicine Group in a research note on Monday, April 10th.
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at 8.60 on Friday. Cellular Biomedicine Group has a 12-month low of $5.05 and a 12-month high of $15.68. The stock’s market capitalization is $122.89 million. The stock has a 50 day moving average of $7.23 and a 200 day moving average of $10.77.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.